Expert Insights From ACC 2022: How New Data in HFrEF Could Influence Your Practice
  • CME

April 2-4, 2022; Washington, DC
Should you recommend a low-sodium diet for patients with heart failure? How could EHR alerts help more patients achieve GDMT? Here’s my take on new data from ACC 2022 addressing these questions and more.
Lee R. Goldberg, MD, MPH, FACC
Physicians: maximum of 0.5 AMA PRA Category 1 Credits
Released: April 20, 2022 Expiration: April 19, 2023

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply new key findings from HFrEF clinical research to the care of patients with HFrEF as appropriate

Acknowledgements

Supported by an educational grant from
Merck Sharp & Dohme Corp.

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Lee R. Goldberg, MD, MPH, FACC

Professor of Medicine
Division of Cardiovascular Medicine
Department of Medicine
Section Chief, Advanced Heart Failure and Cardiac Transplant
University of Pennsylvania
Philadelphia, Pennsylvania

Lee R. Goldberg, MD, MPH, FACC, has disclosed that he has received funds for research support from Zoll/Respicardia and consultant/advisor/speaker fees from Abbott, VisCardia, and Zoll/Respicardia.

Staff

Erin Puritz, PharmD
Erin Puritz, PharmD, has no relevant conflicts of interest to report.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.
Ruth Cohen Cooper, CHCP

Vice President, Science and Strategy

Ruth Cohen Cooper, CHCP, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for cardiology-based physicians and advanced practice providers, primary care professionals, and other healthcare professionals who care for patients with heart failure.

Goal

The goal of this program is to increase the knowledge and competence of learners regarding important treatment advances in the care of patients with HFpEF and HFrEF through an exploration of new data from key clinical studies presented at ACC 2022 and expert discourse on their application to the care of patients with heart failure.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 20, 2022, through April 19, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Expert commentary on management and challenges when treating patients with anemia of CKD, from Clinical Care Options (CCO)

person default Ajay Singh, MBBS, FRCP, MBA Released: November 28, 2022

Unlocked downloadable slides featuring experts insight on the management of patients with obesity from Clinical Care Options (CCO).

Caroline Apovian, MD Ken Fujioka, MD Released: November 2, 2022

Concise microlearning module featuring expert insight on the cardiorenal benefits of SGLT2 inhibitors in T2D from Clinical Care Options (CCO)

Jennifer B. Green, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: July 12, 2022 Expired: July 11, 2023

Unlocked downloadable slides featuring an overview of the cardiorenal benefits of SGLT2 inhibitors in patients with type 2 diabetes, from Clinical Care Options (CCO)

Jennifer B. Green, MD Released: July 12, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings